申请人:Aktiebolaget Astra
公开号:US05523475A1
公开(公告)日:1996-06-04
The present invention relates to novel derivatives of 3-hydroxyanthranilic acid, 3-HANA, of the general formula I ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and selected from H, alkyl, aryl and arylalkyl; X and Y are the same or different and selected from alkoxy, aryloxy, alkyl, alkylthio, arylthio, fluoroalkyl, halogen, cyano, OSO.sub.2 CH.sub.3, OSO.sub.2 CF.sub.3, OCF.sub.3 and SCF.sub.3 with the proviso that the compound of formula I wherein R.sup.1 and R.sup.2 =H, X=Br and Y=Me is excluded; or a pharmaceutically acceptable salt thereof, methods and intermediates for their preparation, novel pharmaceutical compositions and the use thereof for inhibiting the enzyme 3-hydroxyanthranilate oxygenase, 3-HAO, responsible for the production of the endogenous neurotoxin quinolinic acid, QUIN.
本发明涉及3-羟基蒽醌酸的新衍生物,3-HANA,其通式为I
其中R^1和R^2相同或不同,并且选择自H、烷基、芳基和芳基烷基;X和Y相同或不同,并选择自烷氧基、芳氧基、烷基、烷基硫、芳基硫、氟烷基、卤素、氰基、OSO.sub.2 CH.sub.3、OSO.sub.2 CF.sub.3、OCF.sub.3和SCF.sub.3,但其中当R^1和R^2=H、X=Br和Y=Me时,排除通式I的化合物;或其药学上可接受的盐,以及其制备方法和中间体,新型药物组合物及其用途,用于抑制酶3-羟基蒽醌酸氧化酶,3-HAO,负责产生内源性神经毒素喹啉酸,QUIN。